SGLT2 inhibitors have become a fundamental aspect of managing T2DM, particularly in patients with existing cardiovascular disease or heart failure, due to their significant ability to reduce major adverse cardiovascular events and heart failure events. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.